Mak, Gabriel
Soria, Jean-Charles
Blagden, Sarah P.
Plummer, Ruth
Fleming, Ronald A.
Nebot, Noelia
Zhang, Jianping
Mazumdar, Jolly
Rogan, Debra
Gazzah, Anas
Rizzuto, Ivana
Greystoke, Alastair
Yan, Li
Tolson, Jerry
Auger, Kurt R.
Arkenau, Hendrik-Tobias
Article History
Received: 22 August 2018
Revised: 21 March 2019
Accepted: 26 March 2019
First Online: 17 April 2019
Competing interests
: At the time of the clinical study, R.A.F, N.N, J.M., D.R., L.Y., J.T., and K.R.A. were employees of GlaxoSmithKline. R.P. and J-C.S. have received honoraria or consultancy fees from GSK. The remaining authors declare no competing interests.
: The study was conducted in accordance with the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice, the Declaration of Helsinki 2008 and applicable country-specific requirements. Prior to the study, ethics committee and institutional review board approval were obtained from MHRA Health Research Authority NRES Committee North West-Haydock (Manchester, UK) and CPP Île-de-France III, Hôpital Tarnier (Paris, France). All subjects provided written informed consent before any study specific procedures were performed.
: Summaries of the study protocol and results are available from ExternalRef removed. Anonymized individual participant data and study documents can be requested for further research from ExternalRef removed.